LABORATORIO REIG JOFRE (RJF) AI Stock Analysis

• Market Cap: €245.01M
• Dividend Yield: 1.4%
• Average Volume (3M): 25.13K
• Price to Earnings (P/E): 22.2
• Beta (1Y): 0.36
• Revenue Growth: 5.10%
• EPS Growth: 20.61%
• Country: ES
• Employees: 1,331
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.04
• Shares Outstanding: 82,219,240
• 10 Day Avg. Volume: 12,911
• 30 Day Avg. Volume: 25,129
• PEG Ratio: 0.55
• Price to Book (P/B): 1.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €3.50
• Price Target Upside: 17.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 62 Neutral
• Price Target: €3.00 ▲(1.01%Upside)

The overall stock score of 66.25 reflects strong financial health and growth potential as the most significant factor, supported by robust revenue growth and cash flow generation. The technical analysis suggests neutral to slightly bearish momentum, while the valuation indicates possible overvaluation concerns. The absence of new guidance or corporate events means these components do not influence the score.

LABORATORIO REIG JOFRE Business Overview & Revenue Model

Company Description

Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan Despí, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.

How the Company Makes Money

Reig Jofre generates revenue through the development, production, and sale of pharmaceutical and healthcare products. The company's key revenue streams include the sale of prescription medications, over-the-counter products, and consumer health products. It invests in research and development to innovate and expand its product portfolio, which helps maintain its competitive edge in the markets it serves. Additionally, Reig Jofre often relies on strategic partnerships and collaborations with other pharmaceutical companies and healthcare providers to enhance its distribution networks and market reach, thereby contributing to its overall earnings.

LABORATORIO REIG JOFRE Financial Statement Overview

Summary

LABORATORIO REIG JOFRE shows a robust financial performance with strong revenue and profit growth. The balance sheet is solid with manageable leverage, and cash flow generation is healthy, providing ample liquidity for operations and investments.

Income Statement

The company has demonstrated a strong revenue growth trajectory, with a notable increase from €316.09M to €338.90M year-over-year, marking a 7.22% growth rate. Gross Profit Margin is healthy at 57.73%, indicating efficient cost management. The Net Profit Margin improved to 3.06%, reflecting better profitability. EBIT and EBITDA margins are stable at 3.72% and 10.68% respectively, though room for improvement remains.

Balance Sheet

The Debt-to-Equity ratio is reasonable at 0.27, indicating a balanced leverage. Return on Equity is moderate at 4.85%, suggesting efficient asset utilization. The company maintains a good Equity Ratio of 62.06%, supporting financial stability. Overall, the balance sheet reflects sound financial health with manageable debt levels.

Cash Flow

Operating Cash Flow has increased significantly to €31.34M, showcasing strong cash-generating ability. Free Cash Flow to Net Income ratio is 1.02, indicating effective cash management. Free Cash Flow grew by 66.37%, reflecting improved financial flexibility. The company is well-positioned to meet its short-term obligations and invest in growth opportunities.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	338.89M	316.09M	271.15M	236.23M	230.08M
Gross Profit	195.68M	175.03M	69.58M	144.98M	140.40M
EBITDA	36.18M	33.89M	30.44M	24.66M	24.31M
Net Income	10.38M	9.41M	8.11M	5.09M	5.67M
Balance Sheet
Total Assets	344.85M	330.55M	321.19M	324.98M	317.15M
Cash, Cash Equivalents and Short-Term Investments	16.08M	6.36M	6.45M	5.16M	11.69M
Total Debt	58.52M	53.49M	61.24M	67.38M	57.02M
Total Liabilities	130.90M	126.29M	122.94M	136.46M	132.67M
Stockholders Equity	213.97M	204.35M	194.63M	188.59M	184.55M
Cash Flow
Free Cash Flow	10.56M	6.34M	4.75M	-5.26M	6.55M
Operating Cash Flow	31.34M	19.11M	16.15M	14.50M	22.50M
Investing Cash Flow	-31.96M	-12.88M	-12.72M	-34.70M	-30.70M
Financing Cash Flow	5.59M	-7.16M	-2.04M	13.67M	9.62M

LABORATORIO REIG JOFRE Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.97
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:RJF, the sentiment is Negative. The current price of 2.97 is below the 20-day moving average (MA) of 3.02, below the 50-day MA of 3.08, and above the 200-day MA of 2.79, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.27 is Neutral, neither overbought nor oversold. The STOCH value of 22.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:RJF.

LABORATORIO REIG JOFRE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RJF	62 Neutral	€245.01M	22.19	5.11%	1.40%	5.10%	20.61%
Sector *	57 Neutral	£4.82B	6.64	-62.36%	5.43%	34.03%	6.31%
0O9B	―	€2.35B	228.33	0.69%	1.44%	―	―
0K9H	―	€1.42B	12.73	16.04%	6.07%	―	―
0ILL	―	€2.82B	20.58	25.24%	1.35%	―	―
ORN	―	€218.20M	―	-5.48%	―	―	―
A2T	―	€220.34M	―	-11.64%	―	―	―

LABORATORIO REIG JOFRE Corporate Events

Reig Jofre Announces Free Capital Increase and Flexible Dividend Options

Reig Jofre announced the execution of a free capital increase, allowing shareholders to receive preferential subscription rights. Shareholders can choose to exchange these rights for new shares, sell them for cash to the company or on the market, or combine these options, with the trading period for these rights set from May 15 to 29, 2025.

Reig Jofre Announces Board Secretary Change

LABORATORIO REIG JOFRE, S.A. announced the resignation of Mr. Adolf Rousaud Viñas as Non-Director Secretary of the Board of Directors, effective April 30, 2025, due to personal reasons. The company expressed gratitude for his contributions to the board’s evolution and professionalization. Mr. Iñaki Frías Inchausti, a practicing lawyer, has been appointed as the new Non-Director Secretary, following a favorable report from the Appointments, Remuneration, and Sustainability Committee.

Reig Jofre Announces Flexible Dividend Options Through Capital Increase

Reig Jofre has announced the execution of a capital increase through a ‘scrip dividend’ or flexible dividend, allowing shareholders to receive either free shares or cash equivalent to a dividend payment. This move, approved by the Board of Directors, aims to provide shareholders with multiple options for their dividends, potentially impacting the company’s capital structure and shareholder value.

REIG JOFRE’s Q1 2025 Results: Operational Gains and International Expansion

REIG JOFRE reported a 12% increase in net results for the first quarter of 2025, driven by operational improvements and international growth, with revenues reaching 88 million euros. The company’s strategic focus on international markets, particularly in Europe and Asia, has led to a significant increase in sales outside Spain, now accounting for 60% of total revenues, while domestic sales decreased by 10%.

REIG JOFRE Secures 13 Million Euro Grant for Pharmaceutical Innovation

REIG JOFRE has been awarded a 13 million euro grant from the CDTi as part of the European IPCEI Med4Cure project, aimed at boosting pharmaceutical innovation. This grant supports REIG JOFRE’s EMINTECH project, which focuses on tackling global health challenges such as antimicrobial resistance and rare diseases through advanced therapies and cutting-edge technologies, enhancing the company’s strategic alignment with European health objectives.